OmniAb Inc（OABI）財務資料OABIOmniAb Inc

OmniAb Inc (OABI) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is License and milestone revenue, accounting for 70.9% of total sales, equivalent to $9.52M. Other significant revenue streams include Service revenue and xPloration revenue. Understanding this composition is critical for investors evaluating how OABI navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, OmniAb Inc maintains a gross margin of 72.69%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -49.47%, while the net margin is -43.67%. These profitability ratios, combined with a Return on Equity (ROE) of -16.95%, provide a clear picture of how effectively OABI converts its operational activities into shareholder value.

In the context of the broader market, OABI competes directly with industry leaders such as ANL and LINC. With a market capitalization of $694.97M, it holds a significant position in the sector. When comparing efficiency, OABI's gross margin of 72.69% stands against ANL's 100.00% and LINC's 58.17%. Such benchmarking helps identify whether OmniAb Inc is trading at a premium or discount relative to its financial performance.

OmniAb reported total revenue of $13.4 million for Q2 2026, a 244% increase from $3.9 million in Q2 2025. The gross margin improved to 72.69% in Q2 2026, up from 10.44% in Q2 2025, indicating a recovery in profitability. However, net income remains negative, with a loss of -$5.9 million in Q2 2026.